Aliskiren

被引:3
|
作者
Anderson, David Leif [1 ]
机构
[1] Dept Med Informat, Barcelona 08025, Spain
关键词
D O I
10.1358/dot.2007.43.12.977448
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aliskiren (CGP-60536 or SPP1100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be introduced in more than a decade. Aliskiren taken once a day, alone or in combination with other anti hypertensive agents, has been shown to be effective in reducing blood pressure and is generally well tolerated. Based on an extensive clinical trials program, aliskiren was approved for the treatment of hypertension in March 2007 (as Tekturna((R)); Novartis Pharmaceuticals, East Hanover, NJ, USA) by the U.S. Food and Drug Administration and in August 2007 (as Rasilez((R)), Enviage((R)), Sprimeo((R)), Tekturna((R)) and Riprazo((R)), all from Novartis) for the treatment of essential hypertension by the European Commission. Although the indication for aliskiren is treatment of essential hypertension, benefits similar to those demonstrated with certain angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are anticipated for aliskiren. Some of the 44 trials with aliskiren are listed in Table II. Inhibition of renin, which is the first and rate-limiting step in the renin-angiotensin pathway has theoretical advantages over either ACE inhibitors or ARBs. (c) 2007 Prous Science. All rights reserved.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 50 条
  • [21] Renin inhibition with aliskiren
    Wuerzner, Gregoire
    Azizi, Michel
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (04) : 426 - 430
  • [22] Aliskiren and kidney function
    Pagel, H.
    Tscherpel, C.
    Patejdl, R.
    Noack, T.
    ACTA PHYSIOLOGICA, 2016, 216
  • [23] Aliskiren in the Management of Hypertension
    Barrios, Vivencio
    Escobar, Carlos
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (06) : 349 - 358
  • [24] Aliskiren Trial Terminated
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1382): : 5 - 5
  • [25] Aliskiren (Tekturna) for hypertension
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1258): : 29 - 31
  • [26] Antihypertensive therapy with aliskiren
    Luft, F. C.
    Weinberger, M. H.
    KIDNEY INTERNATIONAL, 2008, 73 (06) : 679 - 683
  • [27] Aliskiren and angioedema Comment
    不详
    AUSTRALIAN PRESCRIBER, 2010, 33 (03) : 67 - 67
  • [28] Effectiveness and Safety of Aliskiren and Aliskiren Hydrochlorothiazide (HCT) in a Multiethnic, Real-World Setting
    Maddury, Srinivasa Rao
    Pande, Abhay
    Haque, K. M. H. S. Sirajul
    Echtay, Akram
    Go, Loewe
    Gulzar, Tashbeeb
    Kadwa, Mahomed
    Hristoskova, Sashka
    ADVANCES IN THERAPY, 2013, 30 (02) : 176 - 189
  • [29] Aliskiren accumulates in renin secretory granules: Evidence for the release of aliskiren-bound renin following exposure of renin-synthesizing cells to aliskiren
    Krop, M.
    Danser, A. H. J.
    JOURNAL OF HYPERTENSION, 2008, 26 : S429 - S429
  • [30] Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders
    Nickenig, Georg
    Simanenkov, Vladimir
    Lembo, Giuseppe
    Rodriguez, Pablo
    Salko, Thomas
    Ritter, Shannon
    Zhang, Jack
    BLOOD PRESSURE, 2008, 17 : 31 - 40